Evidence map›Paper›PMID 29774158›Full record

ArticleUnited European gastroenterology journal2018

Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.

Martine De Vos, Barbara Dhooghe, Severine Vermeire, Edouard Louis, Fazia Mana, Ann Elewaut, Peter Bossuyt, Filip Baert, Catherine Reenaers, Marc Van Gossum and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Radioimmune Imaging of αPharmaceutics · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

Martine De VosDepartment of Gastroenterology and Hepatology, University Hospital Ghent, Belgium.
Barbara DhoogheDepartment of Gastroenterology and Hepatology, University Hospital Ghent, Belgium.
Severine VermeireDepartments of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Belgium.
Edouard LouisDepartment of Gastroenterology, University Hospital of Liège, Belgium.
Fazia ManaDepartment of Gastroenterology, University Hospital Brussels (Jette), Belgium.
Ann ElewautDepartment of Gastroenterology, AZ Groeninge, Kortrijk, Belgium.
Peter BossuytImelda GI Clinical Research Centre, Imeldaziekenhuis Bonheiden, Belgium.
Filip BaertDepartment of Gastroenterology, AZ Delta, Roeselare, Belgium.
Catherine ReenaersDepartment of Gastroenterology, University Hospital of Liège, Belgium.
Marc Van GossumDepartment of Gastroenterology, ULB Erasme, Brussels, Belgium.
Elisabeth MackenDepartment of Gastroenterology, University Hospital Antwerp, Belgium.
Marc FerranteDepartments of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Belgium.
Pieter HindryckxDepartment of Gastroenterology and Hepatology, University Hospital Ghent, Belgium.
Olivier DewitDepartment of Hepato-Gastro-Enterology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Tom HolvoetDepartment of Gastroenterology and Hepatology, University Hospital Ghent, Belgium.
Denis FranchimontDepartment of Gastroenterology, ULB Erasme, Brussels, Belgium.
Belgian Inflammatory Bowel Disease Research and Development (BIRD)
Ghent University Hospital · BEErasmus Hospital · BEKU Leuven · BEUniversity of Liège · BEAntwerp University Hospital · BEAZ Delta · BEAZ Groeninge · BECliniques Universitaires Saint-Luc · BEImelda Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVedolizumab is a recently available monoclonal antibody targeting α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).

objectiveThe objective of this article is to evaluate the efficacy of vedolizumab induction therapy in anti-TNF-refractory/intolerant UC and CD patients in real life.

methodsA cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015). Rates of clinical response and remission were retrospectively evaluated at Week 10 for UC and Week 14 for CD using the physician's global assessment (PGA), Mayo score and Harvey Bradshaw index (HBI) or Crohn's disease activity score (CDAI) scores.

resultsEighty-four patients (29 UC, 55 CD) had sufficient data for analysis. For UC patients, clinical response was observed in 76% based on PGA and 59% based on the Mayo score. The corresponding percentages for CD patients were 80% for PGA and 65% for HBI/CDAI. Clinical remission rates were 10% and 40% for UC and CD, respectively. Steroid-free remission was observed in respectively 10% and 35%. Globally, corticosteroids were stopped in 14 out of 48 patients (29%). No new safety signals were reported.

conclusionUp to 70% TNF-refractory/intolerant UC and CD patients achieved a clinical response after 10 to 14 weeks of vedolizumab treatment in this real-life cohort.

Indexed as

inflammatory bowel diseaseobservational studyrefractory patientsVedolizumab

Identifiers

PMID29774158
PMCPMC5949962
OpenAlexW2740875885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.